
Congenica
Total Raised
$85.39MInvestors Count
21Deal Terms
2Funding, Valuation & Revenue
13 Fundings
Congenica has raised $85.39M over 13 rounds.
Congenica's latest funding round was a Acquired for on September 2, 2025.
Congenica's 2024 revenue was $35M. Congenica's most recent revenue is from 2024.
Sign up for a free demo to see revenue data from 2024 and more.
Date | Round | Amount | Investors | Valuation Valuations are submitted by companies, mined from state filings or news, provided by VentureSource, or based on a comparables valuation model. | Revenue | Sources |
|---|---|---|---|---|---|---|
9/2/2025 | Acquired | 5 | ||||
9/19/2023 | Biz Plan Competition - II | $0.08M | $35M FY 2024 | |||
9/21/2021 | Biz Plan Competition | 2 | ||||
3/3/2021 | Series C - II | |||||
11/9/2020 | Series C |
Date | 9/2/2025 | 9/19/2023 | 9/21/2021 | 3/3/2021 | 11/9/2020 |
|---|---|---|---|---|---|
Round | Acquired | Biz Plan Competition - II | Biz Plan Competition | Series C - II | Series C |
Amount | $0.08M | ||||
Investors | |||||
Valuation | |||||
Revenue | $35M FY 2024 | ||||
Sources | 5 | 2 |
Congenica Deal Terms
2 Deal Terms
Congenica's deal structure is available for 2 funding rounds, including their Series B from February 27, 2017.
Round | Series B | Series A |
|---|---|---|
Funding Date | ||
Pre-Money Valuation | ||
Post-Money Valuation | ||
Amount Raised | ||
Shares Authorized | ||
Issuance Price | ||
Dividend Rate | ||
Liquidation Preferences | ||
Liquidation Price | ||
Participation | ||
Conversion Price | ||
Anti Dilution | ||
General Voting | ||
Board Voting | ||
Par Value |
Round | Funding Date | Pre-Money Valuation | Post-Money Valuation | Amount Raised | Shares Authorized | Issuance Price | Dividend Rate | Liquidation Preferences | Liquidation Price | Participation | Conversion Price | Anti Dilution | General Voting | Board Voting | Par Value |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Series B | |||||||||||||||
Series A |
Congenica Investors
21 Investors
Congenica has 21 investors. SeqOne invested in Congenica's Acquired funding round.
First funding | Last Funding | Investor | Rounds | Board Seats | Type | Location |
|---|---|---|---|---|---|---|
9/2/2025 | 9/2/2025 | 1 Acquired | Corporation | France | ||
9/19/2023 | 9/19/2023 | 1 Biz Plan Competition - II | Incubator/Accelerator | Massachusetts | ||
9/21/2021 | 9/21/2021 | 1 Biz Plan Competition | Business Plan Competition | United Kingdom | ||
Venture Capital | United Kingdom | |||||
Venture Capital | United Kingdom |
First funding | 9/2/2025 | 9/19/2023 | 9/21/2021 | ||
|---|---|---|---|---|---|
Last Funding | 9/2/2025 | 9/19/2023 | 9/21/2021 | ||
Investor | |||||
Rounds | 1 Acquired | 1 Biz Plan Competition - II | 1 Biz Plan Competition | ||
Board Seats | |||||
Type | Corporation | Incubator/Accelerator | Business Plan Competition | Venture Capital | Venture Capital |
Location | France | Massachusetts | United Kingdom | United Kingdom | United Kingdom |
Compare Congenica to Competitors

Golden Helix is a bioinformatics firm that provides genomic data analysis software for the life sciences sector. The company offers tools for the annotation, filtering, interpretation, and reporting of genomic variants. Golden Helix's solutions serve various sectors, including commercial testing labs, hospital labs, human genetic research, and pharmaceutical R&D. It was founded in 1998 and is based in Bozeman, Montana.

Geneyx focuses on sequencing (NGS) data analysis and interpretation within the clinical genome research sector. The company offers services for analyzing and interpreting genetic data from whole genome sequencing (WGS), whole exome sequencing (WES), gene panels, and microarrays, utilized by hospitals, commercial laboratories, and researchers in the healthcare and pharmaceutical industries. Geneyx was formerly known as TGex. It was founded in 2018 and is based in Wilmington, Delaware.
VarSome is a company that engages in genomic variant discovery and interpretation within the healthcare and research sectors. It provides a platform for the discovery, annotation, and interpretation of next-generation sequencing (NGS) data related to whole genomes, exomes, and gene panels. VarSome serves healthcare professionals and researchers in the genomics community, offering tools for variant classification and a knowledge base with over 140 data resources. It was founded in 2016 and is based in Lausanne, Switzerland.

SeqOne focuses on clinical genomic analysis within the healthcare sector. Its platform provides bioinformatics tools for the analysis of high-throughput sequencing data to support diagnostics in oncology, rare, and inherited diseases. SeqOne's solutions aim to improve the performance of genomic labs and healthcare professionals. It was founded in 2017 and is based in Montpellier, France.

Verily focuses on providing data-integrated solutions. The company offers clinical trial recruitment and management, multimodal data analytics, population-level disease monitoring, artificial intelligence (AI)-integrated chronic care solutions, and precision health risk management. Verily serves sectors such as biotechnology and pharma, healthcare payers and providers, public health agencies, and employers. Verily was formerly known as Google Life Sciences. It was founded in 2015 and is based in Dallas, Texas.

DNAnexus operates in precision health data management. It provides solutions in the biotechnology and healthcare sectors. The company's offerings include a cloud-based platform for managing, analyzing, and collaborating on multimodal omics data, with a suite of bioinformatics tools and artificial intelligence (AI) capabilities. DNAnexus serves various sectors, including pharmaceutical, biotech, clinical diagnostics, academic medical centers, commercial data businesses, biobanks, and regulatory sectors. It was founded in 2009 and is based in Mountain View, California.
Loading...

